Recent Treatments of Interstitial Lung Disease with Systemic Sclerosis

Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine

Review

Hidekata Yasuoka¹ 

[1] Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku, Tokyo, Japan.;

关键词: systemic sclerosis;    interstitial lung disease;    pulmonary hypertension;   

DOI  :  10.4137/CCRPM.S23315

 received in 2015-06-03, accepted in 2015-09-23,  发布年份 2015

来源: Sage Journals

【 摘 要 】

Systemic sclerosis (SSc) is a disorder characterized by immune dysfunction, microvascular injury, and fibrosis. Organ involvement in patients with SSc is variable; however, pulmonary involvement occurs in up to 90% of patients with SSc. Interstitial lung disease (ILD) is a major cause of mortality and, thus, a major determinant in the prognosis of patients with SSc. This review summarizes current findings about the characteristics of ILD in patients with SSc, selection of patients with SSc-ILD who are candidates for the treatment, and current treatment options.

【 授权许可】

CC BY-NC   
© 2015 SAGE Publications.

【 图 表 】

Figure 1.

Figure 3.

Figure 6.

Figure 5.

Figure 3a.

Figure 4.

Figure 1b.